Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Feb;39(1):12-15.
doi: 10.4103/lungindia.lungindia_671_20.

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up

Pankaj Jariwala  1 , Venkata Nagarjuna Maturu  2 , Kartik Pandurang Jadhav  1 , Arshad Punjani  3 , Harikishan Boorugu  3
Affiliations

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up

Pankaj Jariwala et al. Lung India. 2022 Jan-Feb.

Abstract

Background: The effectiveness and safety of macitentan, an endothelin-receptor antagonist (ERA) in the treatment of pulmonary arterial hypertension (PAH), has been demonstrated in numerous randomized clinical trials including SERAPHIN, focused on the reduction of morbidity and mortality.

Objectives: Our aim was to demonstrate the clinical and echocardiographic progression using macitentan in Indian patients with PAH.

Settings and design: It was a retrospective study of 20 patients with multiple etiologies of PAH who had begun macitentan in routine clinical practice from a single center. There were 55% of patients with existing PAH therapies.

Subjects and methods: The World Health Organization functional class (WHO-FC), 6-min walking distance, N-terminal prohormone of brain natriuretic peptide level (NT-pro-BNP), and echocardiographic data such as tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressure (sPAP), and the occurrence of pericardial effusion were collected at baseline and 12-month follow-up. The statistical analysis was performed using SPSS software.

Results: Of the 20 PAH patients, 70% were women. The majority were in WHO FC II (50%), while 35% were in FC III and 15% were in FC IV. The mean age was 43.4 years at the start of the therapy with macitentan. After 6 months of macitentan therapy, 85% showed substantial improvement in their FC, each increased its 6-min walking distance test (P < 0.0001), and there was a significant reduction in plasma levels of NT-pro BNP (P < 0.0001). There has also been an improvement in echocardiographic parameters such as TAPSE and sPAP (P < 0.0001).

Conclusions: Our findings indicate that macitentan has been well tolerated and beneficial in Indian patients with PAH and further, future research is required to verify these results.

Keywords: Echocardiography; N-terminal prohormone of brain natriuretic peptide; endothelin-receptor antagonist; macitentan; pulmonary arterial hypertension; pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Comparison of World Health Organization functional class at baseline and 12-month follow-up
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327:736–45. - PubMed
    1. Khadka A, Singh Brashier DB, Tejus A, Sharma AK. Macitentan: An important addition to the treatment of pulmonary arterial hypertension. J Pharmacol Pharmacother. 2015;6:53–7. - PMC - PubMed
    1. Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7:e47662. - PMC - PubMed
    1. Patel T, McKeage K. Macitentan: First global approval. Drugs. 2014;74:127–33. - PubMed
    1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed) 2016;69:177. - PubMed